The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 141.00
Bid: 140.80
Ask: 141.80
Change: -1.20 (-0.84%)
Spread: 1.00 (0.71%)
Open: 147.80
High: 147.80
Low: 140.80
Prev. Close: 142.20
ELM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Trading Statement

13 May 2021 07:00

RNS Number : 4477Y
Elementis PLC
13 May 2021
 

Elementis plc

AGM Trading Statement

Strong first quarter performance, ahead of expectations

On track for improved financial performance and deleveraging

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues a trading update for the three months ended 31 March 2021 and an update on current trading.

First quarter business performance

In the first quarter of 2021 Group performance has been strong and ahead of expectations. Revenue increased approximately 6% on the prior year period, which was largely before the impact of COVID-19, with the successful execution of self help actions augmented by improved underlying demand, customer restocking and currency tailwinds.

· Coatings revenue increased significantly on the prior year period with strong volumes across all geographies driven by new business wins, improved industrial coatings demand and customer restocking. Margins were robust with pricing actions offsetting raw material cost inflation.

 

· Personal Care performance was as expected, slightly below the prior year period, with customer restocking offset by continued weak category demand for cosmetics and anti-perspirant deodorants due to COVID-19 related social and travel restrictions. Margins were resilient and the start-up of our new plant in India is expected to commence in the third quarter.

 

· Talc performance was broadly in line with the prior year period with strong industrial talc growth, driven by the continued rebound in automotive demand and robust coatings sales, offset by weaker sales to paper end markets.

 

· Chromium revenue was in line with the prior year period due to improved demand and restocking across key industrial end markets such as automotive and leather tanning. While unit pricing was sequentially stable, margins were below the prior year period due to lower pricing outside of North America.

 

Cash generation in the first quarter was in line with expectations and the Group's business model remains highly cash generative.

 

Outlook

 

We have made a strong start to the year, with improved year on year profitability, driven by increased demand across industrial end markets. This positive momentum has continued into the second quarter and demand remains healthy. For the full year, we are confident that further steady demand improvement from H2 2020 levels coupled with our self help actions will drive improved financial performance, towards the top end of consensus expectations*, and a reduction in leverage.

 

 

Commenting on the performance, CEO, Paul Waterman said,

"We have made a good start to 2021 and are on track to deliver an improved financial performance and a reduction in leverage. We will continue to maintain our focus on self-help actions and in 2021 expect to deliver more than $30m of new business opportunities, over 20 new products and $10m of cost savings".

 

 

Enquiries

Elementis plc

James Curran, Investor Relations Tel: 020 7067 2994

 

Tulchan

Martin Robinson/David Allchurch Tel: 020 7353 4200

 

 

* Based on the company compiled consensus, the Board believes current market forecasts for 2021 adjusted operating profit to be in the range of $92m to $103m with an average of $97m.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQLLFFFELZBBD
Date   Source Headline
30th Apr 202411:36 amRNSResult of AGM
30th Apr 20247:00 amRNSFirst quarter trading update
29th Apr 202412:13 pmRNSResponse to open letter from Gatemore
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review
1st Sep 20239:42 amRNSTotal Voting Rights
1st Aug 20239:44 amRNSTotal Voting Rights
27th Jul 20232:16 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSHalf-year Report
20th Jul 202312:58 pmRNSHolding(s) in Company
3rd Jul 202310:21 amRNSTotal Voting Rights
29th Jun 20234:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20239:32 amRNSDirector/PDMR Shareholding
30th May 20238:06 amRNSDirector Declaration
2nd May 20239:37 amRNSTotal Voting Rights
26th Apr 20232:12 pmRNSResult of AGM
26th Apr 20237:00 amRNSAGM Trading Statement
17th Apr 202310:15 amRNSDirector/PDMR Shareholding
17th Apr 202310:10 amRNSDirector/PDMR Shareholding
13th Apr 20234:24 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:28 amRNSDirector Declaration
3rd Apr 20239:34 amRNSTotal Voting Rights
24th Mar 20239:27 amRNSDirector/PDMR Shareholding
22nd Mar 20234:02 pmRNSAnnual Financial Report & Notice of AGM
17th Mar 20232:58 pmRNSAdditional Listing
14th Mar 20237:30 amRNSDirector Declaration
9th Mar 20232:50 pmRNSDirector/PDMR Shareholding
9th Mar 20232:47 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.